https://www.selleckchem.com/GSK-3.html
spectively, which were significantly lower than the control group (52.623 ± 2.441)% and (38.702 ± 1.312)% (P less then 0.05). Conclusion miR-23b can inhibit the proliferation, migration, invasion and vasculogenic mimicry formation, and enhance the sensitivity of lenvatinib drug in human hepatocellular carcinoma cells.Objective To study LIM kinase 1 (LIMK1) expressional condition, and its regulatory effects on the proliferation and metastasis of hepatocellular carcinoma cells and tissues. Methods The online database starBase v3.0 and GEPIA were use
Like
Comment
Share
